It is unsafe to consume alcohol with Tamoral.
Tamoral is highly unsafe to use during pregnancy. Seek your doctor's advice as studies on pregnant women and animals have shown significant harmful effects to the developing baby.
CONSULT YOUR DOCTOR
Tamoral is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Tamoral may cause side effects which could affect your ability to drive. Tamoral may cause tiredness. This may affect your driving ability.
SAFE IF PRESCRIBED
Tamoral is probably safe to use in patients with kidney disease. Limited data available suggests that dose adjustment of Tamoral may not be needed in these patients. Please consult your doctor.
CONSULT YOUR DOCTOR
There is limited information available on the use of Tamoral in patients with liver disease. Please consult your doctor.
Tamoral is an anti-estrogens. It is used in the treatment of breast cancer. It is also used to reduce the risk of breast cancer in women with a high chance of developing it. This medicine helps to slow down the growth and multiplication of cancer cells. Tamoral is also helpful in the treatment of infertility. It can be taken with or without food, but take it at the same time to get the most benefit. It should be taken as your doctor's advice. The dose and how often you take it depends on what you are taking it for. Your doctor will decide how much you need to improve your symptoms. Swallow the tablets whole with a drink of water. You should take this medicine for as long as it is prescribed for you. The most common side effects of this medicine include nausea, skin rash, hot flushes, thinning of hair and tiredness. If these bother you or appear serious, let your doctor know. There may be ways of reducing or preventing them. Some side effects may mean you should inform your doctor immediately include vaginal bleeding, irregular menstrual period and vaginal discharge. It makes birth control pills less effective, hence use a condom and other preventive measures to avoid pregnancy. Before taking this medicine, tell your doctor if you are on treatment of infertility or had a blood clot disorder. Your doctor should also know about all other medicines you are taking as many of these may make this medicine less effective or change the way it works. Tell your doctor if you are pregnant or breastfeeding. Your doctor may perform some blood tests to check liver function and calcium level in the body.
Uses of Tamoral
- Breast cancer
Side effects of Tamoral
- Skin rash
- Hot flashes
- Thinning of hair
- Vaginal discharge
How to use Tamoral
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Tamoral may be taken with or without food, but it is better to take it at a fixed time.
How Tamoral works
Tamoral is a hormone-based medication. It works by binding to estrogen receptors and blocking the effects of estrogen (a natural female hormone) in the breast tissue. This slows down the growth and multiplication of breast cancer cells.
- Tamoral helps treat breast cancer.
- It also reduces the risk of cancer coming back and of getting cancer in the other breast.
- Use a reliable barrier contraceptive method (such as condoms) to prevent pregnancy while you are taking this medicine and for 2 months after you stop taking it.
- Inform your doctor if you are pregnant, planning to conceive or breastfeeding.
- Inform your doctor if your periods become irregular, especially if associated with heavier bleeding.
- Do not stop taking the medicine without talking to your doctor first.
May be taken with or without food.
Oral Breast Cancer Treatment 20 mg daily as a single or in 2 divided doses. Max: 40 mg daily. Continue with adjuvant therapy for at least 5 years For women with ER-positive disease, continuing tamoxifen to 10 years rather than stopping at 5 years produces a further reduction in recurrence and mortality, particularly after year 10 Breast Cancer Prevention Indicated to reduce the incidence of breast cancer in women at high risk for breast cancer; high risk is defined as women aged >35 years with a 5-year predicted risk of breast cancer >1.67% (calculated by the Gail Model) Adult: 20 mg daily for 5 yr. Data are limited for use >5 yr in the risk-reduction setting Anovulatory infertility Adult: 20 mg daily on days 2-5 of the menstrual cycle, increase if necessary in subsequent cycles. Max: 80 mg daily. Women w/ irregular menstruation: Initial course may begin on any day and a 2nd course may start 45 days later.
History of DVT or pulmonary embolism. Pregnancy and lactation. Concomitant coumarin-type anticoagulant therapy.
Mode of Action
Tamoxifen, a triphenylethylene derivative, produces a nuclear complex by competitively binding to oestrogen receptors on tumours and other tissue targets thus, decreasing DNA synthesis and inhibiting oestrogen effect. It is only cytostatic rather than cytotoxic due to accumulation of cell in G0 and G1 phases.
Patient w/ leucopenia and thrombocytopenia, hyperlipidaemias. Monitoring Parameters Perform periodic CBC (e.g. platelet counts) and LFTs. Routine gynaecological monitoring and any abnormal symptoms (e.g. abnormal vag bleeding or discharge, pelvic pain, menstrual irregularities). Lactation: not known if excreted in breast milk, do not nurse
>10% Hot flashes (64%),Vaginal discharge (30%),Amenorrhea (16%),Menstrual changes (13%) 1-10% Oligomenorrhea (9%),Cataracts (8%),Bone pain (6%),Nausea (5%),Cough (4%),Edema (4%),Fatigue (4%),Musculoskeletal pain (3%),Ovarian cyst (3%),Depression (2%),Abdominal cramps (1%),Anorexia (1%) <1% Angioedema,Corneal changes,Loss of libido,Endometrial cancer,Pancreatitis,Retinal vein thrombosis,Stroke,Uterine fibroids Potentially Fatal: Blood dyscrasias, cholestasis, hepatitis, hypercalcaemia in patients with bone metastasis, thromboembolic events. Increased risk of endometrial cancer and uterine sarcoma.
Increases dopaminergic effect of bromocriptine. Increased risk of thromboembolic events w/ cytotoxic drugs. Increased risk of bleeding w/ platelet aggregation inhibitors. May mutually reduce effects w/ hormone preparations particularly oestrogens (e.g. OCs). Reduced plasma levels w/ CYP3A4 inducers (e.g rifampicin) and CYP2D6 inhibitors. Increased plasma levels w/ CYP3A4 inhibitors. Potentially Fatal: Significant increase in anticoagulant effect w/ coumarin-type anticoagulants (e.g. warfarin).
More from Techno Drugs LTD.
The information provided herein is accurate, updated and complete as per the best practices of the Company. Please note that this information should not be treated as a replacement for physical medical consultation or advice. We do not guarantee the accuracy and the completeness of the information so provided. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company. We do not take any responsibility for the consequences arising out of the aforementioned information and strongly recommend you for a physical consultation in case of any queries or doubts.